Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

Raw authenticity can be disruptive in life sciences workplaces, but learning corporate fluency and stylistic pivots can help leaders become strategically authentic, writes Hope Mueller.

On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

As anxiety disorders become more common and stress from the diverse impacts of the COVID-19 pandemic threaten the mental/emotional well-being of Americans everywhere, it is clear that the current ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

Empirical research comparing corporate and academic spin-offs consistently shows that corporate-originated ventures outperform their academic counterparts in terms of growth and survival. This ...